Two-Drug Maintenance May Not Pan Out in NSCLC (CME/CE)
(MedPage Today) -- Combination maintenance therapy with erlotinib (Tarceva) and bevacizumab (Avastin) modestly delayed progression but not death in advanced non-small cell lung cancer, the ATLAS trial showed.
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Hematology | Lung Cancer | Non-Small Cell Lung Cancer | Tarceva